TP53 and fatty liver disease: Again, along with the metabolic data in the situation of choline supplementation (Supplemental Figure 1, C–E), dietary choline–treated mice did not develop fatty liver, and there were no differences in liver dysfunction, body weight, or liver weight between p53+/+ and p53–/– mice (Figure 1A and Supplemental Figure 7, K–N).